Acute Hemorrhagic Encephalitis Related to COVID-19

Alan Chalil, MD, MSc, Carmen S. Baker, MD, Robert B. Johnston, MD, Caroline Just, MD, FRCPC, Derek B. Debicki, MD, PhD, FRCPC, Michael S. Mayich, MD, FRCPC, Karen J. Bosma, MD, FRCPC, and David A. Steven, MD, MPH, FRCSC, FACS

Correspondence
Dr. Steven
david.steven@lhsc.on.ca

Neurology: Clinical Practice April 2021 vol. 11 no. 2 e147-e151 doi:10.1212/CPJ.0000000000000900

Abstract

Purpose of Review

The novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the most critical public health challenge in recent history. In this report, we present a case of suspected acute hemorrhagic encephalitis with bilateral intracranial hemorrhages associated with coronavirus disease 2019 (COVID-19) infection.

Recent Findings

A 48-year-old female COVID-19–positive patient developed acute changes in her neurologic status. A head CT with CT angiography demonstrated extensive bilateral parietal and occipital intraparenchymal hemorrhage with intraventricular extension and acute hydrocephalus. The patient was treated with an external ventricular drain, and a CSF sample was tested for SARS-CoV-2 but was found to be negative.

Summary

The underlying mechanism for developing acute hemorrhagic encephalitis in viral illnesses may be autoimmune in nature and warrants further investigation. The initial neurologic presentation of COVID-19–related hemorrhagic encephalitis is altered level of consciousness, which may prompt further neurologic examination and imaging to exclude this feature.

Coronavirus disease 2019 (COVID-19) is a newly identified respiratory illness caused by a novel coronavirus, SARS-CoV-2.¹ Since the first reported cases in December 2019, COVID-19 has grown into a global pandemic and has become one of the most critical public health challenges in modern history.¹ Although current data suggest that as many as 93% of infected individuals may be asymptomatic,² symptoms generally include fever, dry cough, sore throat, and diarrhea. Serious complications can arise from COVID-19 infection, including pneumonia, acute respiratory distress syndrome, multiorgan failure, and death.³

There are relatively limited data addressing the neurologic complications of COVID-19.^{4,5} The most robust study to date suggests that approximately 1/3 of patients can have neurologic complications that can vary from benign (headache and dizziness) to altered mental status and seizures.⁵ In addition, there have been reports of encephalopathy in elderly patients⁴ and 1 case report of hemorrhagic necrotizing encephalopathy related to COVID-19.⁶

MORE ONLINE

COVID-19 Resources

For the latest articles, invited commentaries, and blogs from physicians around the world

[NPublic.org/COVID19](https://npublications.org/COVID19)

Department of Clinical Neurological Sciences (AC, RBJ, CJ, DBD, DAS), Schulich School of Medicine and Dentistry, Western University; Department of Physical Medicine and Rehabilitation (CSB), Schulich School of Medicine and Dentistry, Western University; Department of Medical Imaging (MSM), Schulich School of Medicine and Dentistry, Western University; Department of Medicine (KJB), Schulich School of Medicine and Dentistry, Western University; and Department of Epidemiology and Biostatistics (DAS), Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

Funding information and disclosures are provided at the end of the article. Full disclosure form information provided by the authors is available with the full text of this article at [Neurology.org/cp](https://neurology.org/cp).

In this current report, we present the unique case of a 48-year-old patient who developed acute hemorrhagic encephalitis with bilateral intracranial hemorrhage associated with COVID-19 infection.

Case Presentation

A 48-year-old previously healthy woman was admitted to our institution after experiencing 2 weeks of myalgia, dry cough, shortness of breath, and fever. On presentation, the patient was hypoxic, prompting intubation and admission to the intensive care unit where COVID-19 status was confirmed to be positive by SARS-CoV-2 PCR testing. Pulmonary CT demonstrated characteristic features including extensive bilateral ground glass opacity with areas of consolidation and interlobular septal thickening (figure 1). The patient received hydroxychloroquine (oral, 2 doses of 400 mg and 5 doses of 200 mg) and 2 doses of tocilizumab. Hydroxychloroquine was stopped due to development of supraventricular tachycardia and prolonged QT interval on electrocardiogram. Bloodwork demonstrated markedly elevated D-dimers with severe hypoxemia, and she was started on IV heparin infusion on postadmission day 10, with only a single partial thromboplastin time outside of therapeutic range, which was promptly corrected. Bloodwork also demonstrated elevated ferritin at 920 µg/L and a mildly elevated CRP of 11.7 mg/L. On postadmission day 15, she was found to have equal and nonreactive pupils bilaterally with

absent cough, gag, and corneal reflexes. A head CT with CT angiography demonstrated extensive bilateral parietal and occipital intraparenchymal hemorrhage with intraventricular extension and acute hydrocephalus (figure 2). There was no evidence of an underlying vascular lesion including venous thrombus or aneurysm. Heparin infusion was stopped immediately and reversed with protamine sulfate. Hyperosmolar therapy was initiated, and an external ventricular drain (EVD) was inserted for intracranial pressure management. Post-EVD insertion, the patient's brainstem reflexes returned, and she was demonstrating extensor posturing to central pain. A repeat CT scan 48 hours later demonstrated stability of the hemorrhages. MRI failed to demonstrate any underlying ischemia but showed cortical gadolinium enhancement with hyperintense T2 and fluid-attenuated inversion recovery signal surrounding the hemorrhages, in keeping with vasogenic edema previously seen on CT (figure 3). PCR testing on CSF taken from the EVD within 24 hours of insertion was negative for SARS-CoV-2 (table). The CSF had $76 \times 10^6/L$ nucleated cells (65% neutrophils) in the presence of $33,000 \times 10^6/L$ erythrocytes. Of note, the CSF immunoglobulin G (IgG) ratio was 0.35 with an IgG index of 1.05. A digital subtraction angiogram was not performed due to the patient's COVID-19 status and unstable condition. The patient was eventually extubated and is currently recovering with severe neurologic deficits. She is currently undergoing rehabilitation.

Discussion

One of the biggest challenges facing physicians and health care workers addressing the COVID-19 pandemic is the wide variability in presenting features, which range from completely asymptomatic individuals to severe acute respiratory distress requiring mechanical ventilation, unconventional treatments, and extensive life-saving measures.³ Features attributable to CNS involvement by COVID-19 are rare but were described in an early population-based study from Wuhan.

We present a suspected case of acute hemorrhagic encephalitis in a previously healthy 48-year-old COVID-19-positive patient. Acute hemorrhagic encephalitis is believed to be a

Figure 1 Unenhanced Axial CT of the Thorax

An axial image through the level of the carina demonstrating bilaterally extensive ground-glass opacity with early consolidation and interlobular septal thickening.

Figure 2 Unenhanced CT of the Head

Axial and coronal reformatted unenhanced CT images demonstrating extensive intraparenchymal hemorrhage in bilateral parietal and occipital lobes with intraventricular extension and acute hydrocephalus.

DWI-ADC images (A and B) demonstrating diffusion restriction limited to areas of hemorrhage demonstrated on MPGR images (C). T2 images (D) demonstrate extensive associated edema. Postcontrast T1 images (F) demonstrate extensive enhancement in addition to intrinsic T1 related to blood products on precontrast images (E), including involvement of the cortex. ADC = apparent diffusion coefficient; DWI = diffusion-weighted imaging; MPGR = multiplanar gradient recalled acquisition.

postinfectious process that is a severe variant of acute disseminated encephalomyelitis and has been described in other viral respiratory infections such as H1N1 Influenza. Another similar entity is acute necrotizing hemorrhagic encephalopathy, although lack of thalamic involvement in our case makes this less likely.⁷⁻⁹

The first case of acute hemorrhagic encephalitis associated with COVID-19 was reported in Detroit, Michigan, in March 2020.⁶ In that case, thalamic involvement suggested that the underlying diagnosis was acute hemorrhagic necrotizing encephalopathy. The patients are demographically similar; however, the cases differ in location and extent of intracranial features (table). It is suspected that the large bilateral intraparenchymal hemorrhage with intraventricular extension was related to the presence of full anticoagulation. Heparin infusion was initiated because the patient's elevated D-dimer; at that time, anticoagulation was deemed the appropriate treatment.

Imaging was completed to determine the underlying etiology of the bilateral parietal-occipital intraparenchymal hemorrhage. An MRI and a CT angiogram (timed to optimize assessment of arterial and venous phases) demonstrated patency of arterial and venous structures. There was no evidence of vasculopathy, aneurysm (including peripheral mycotic lesions), or vascular malformation. The pattern of edema and hemorrhage was inconsistent with watershed

infarct. Posterior reversible encephalopathy syndrome (PRES) was considered unlikely due to the extensive hemorrhage and progressive nature of the findings despite supportive care. It is noted that the patient was briefly treated with tocilizumab, for which there is 1 case report of associated PRES.¹⁰ No other precipitating factors for PRES were identified. Small vessel vasculitis was not suspected based on the available imaging. A digital subtraction angiogram would have definitively ruled out small vessel vasculitis; however, given the patient's diagnosis and unstable condition, this procedure could not be performed.

Having ruled out other differential diagnoses and with the absence of virus in the CSF, the presumed diagnosis of exclusion was one of acute hemorrhagic encephalitis. There are many proposed mechanisms by which SARS-CoV-2 virus can cause nervous system injury, including neural expression of angiotensin-converting enzyme 2 receptors, retrograde neuronal transport, vascular dissemination, systemic or focal hypoxic injury, or as a consequence of cytokine storm.^{5,11,12} Acute hemorrhagic encephalitis may be related to an autoimmune process with an inflammatory response leading to perivascular demyelination and associated edema, hemorrhage, and necrosis.¹³ Support for this comes from the finding that CSF for viral PCR is often negative, as it was for this patient, which suggests that the process is not due to direct viral infiltration of brain parenchyma.^{13,14} Similarly, the presence of an elevated IgG

Table Comparison of Case Study Patient Demographics Presented Here and in the Literature^{4,6}

	Current study	Poyiadji et al.	Filatov et al.
Diagnosis	Acute hemorrhagic leukoencephalitis	Hemorrhagic encephalopathy	Encephalopathy (nonhemorrhagic)
Age, y	Late 40s	50s	72
Sex	Female	Female	Male
Comorbidities	None	Unknown	Atrial fibrillation Cardioembolic stroke Parkinson disease COPD Recent cellulitis
Presumed source	Community	Travel	Travel
Presenting symptoms	Shortness of breath	Fever, cough, and altered mental status	Fever and cough
Neurologic symptoms	Altered mental status (intubated), then weak cough, poor corneal reflexes	Altered mental status	Decreased level of consciousness
Timeline	2 weeks after initial presentation; 5 days after therapeutic heparin infusion initiated	Unknown	Unknown
Initial CT	Bilateral parieto-occipital hematoma and extensive edema causing hydrocephalus	Hypoattenuation within bilateral medial thalami	Nil acute encephalomalacia (prior stroke)
MRI	No watershed infarct Extensive enhancement and cortical involvement in the hemorrhage area.	Hemorrhagic rim-enhancing lesions within bilateral thalami, medial temporal lobes, and subinsular regions.	
EEG	Mild diffuse slowing characteristic of encephalopathy, rare left temporal epileptiform discharges	Unknown	Diffuse slowing and sharply contoured waves, characteristic of encephalopathy
CSF analysis	Negative for COVID-19 Erythrocytes 33,000 × 10 ⁶ /L IgG ratio 0.35 (0–0.23) IgG index 1.05 (0.25–0.85) Negative for VZV, HSV, and ENV	Traumatic—negative for infection	Negative for infection (WBC 4 [count/mm ³], protein 68 mg/dl, and glucose 75 mg/dl)
Outcome	Extubated with significant neurologic deficits. Currently receiving rehabilitation.	Unknown	In critical condition in the intensive care unit.

Abbreviations: EBV = Epstein-Barr virus; HSV = herpes simplex virus; VZV = varicella zoster virus; WBC = white blood count.

index with elevated CSF IgG ratio⁸ and a neutrophil predominant CSF leukocyte count⁷ is in keeping with an inflammatory process rather than a direct viral effect. However, an inflammatory process could only be confirmed with biopsy, which the patient did not undergo. Furthermore, it is also possible that the CSF neutrophilia was influenced by the presence of intraventricular hemorrhage. Although treatment strategies directed toward mitigating the inflammatory response have been used in acute hemorrhagic encephalitis, such as IV immunoglobulin, plasma exchange, or corticosteroids, the outcomes in the few reported adult cases suggest that prognosis is poor.¹⁴

The extensive hemorrhage was most likely related to the use of systemic anticoagulation. There is ongoing debate regarding the appropriate management of patients with COVID-19 who display features consistent with a prothrombotic state, with or without evidence of tissue thrombosis. The present case

highlights the need for ongoing neurologic surveillance and the clear risk of neurologic complications in patients with COVID-19. This is particularly true when anticoagulation is deemed the appropriate treatment strategy and even more so when clinical assessments are limited because of the use of sedation and paralytics to assist in ventilation.

We present a case of a previously healthy 48-year-old woman with COVID-19 who developed acute hemorrhagic encephalitis, a complication which has been rarely described to this point. The underlying mechanism for developing such complication is believed to be autoimmune or paraviral in nature and warrants further investigation. At present, it appears that the initial neurologic presentation of COVID-19–related hemorrhagic encephalitis is altered level of consciousness, which may prompt further neurologic examination and imaging to exclude this feature. The observed intraparenchymal hemorrhage was most likely

exacerbated by systemic anticoagulation and highlights the potential for neurologic complications in these severely ill patients with COVID-19. These findings may inform risk assessment and medical management in these patients, particularly as it pertains to the use of systemic anticoagulation and to the importance of ongoing neurologic assessment.

Study Funding

No targeted funding reported.

Disclosure

The authors report no disclosures relevant to the manuscript. Full disclosure form information provided by the authors is available with the full text of this article at [Neurology.org/cp](https://www.neurology.org/cp).

Publication History

Received by *Neurology: Clinical Practice* April 28, 2020. Accepted in final form June 26, 2020.

TAKE-HOME POINTS

- Features attributable to CNS involvement by COVID-19 are rare though were described in an early population-based studies.
- Acute hemorrhagic encephalitis is a rare complication of viral illness, including COVID-19.
- The underlying mechanism in acute hemorrhagic encephalitis is poorly understood, but may be related to an autoimmune process.
- Intraparenchymal hemorrhage related to COVID-19 may be exacerbated by systemic anticoagulation.
- The initial neurologic presentation of COVID-19-related hemorrhagic encephalitis is altered level of consciousness, which may prompt further neurologic examination and imaging to exclude this feature.

Appendix Authors

Author	Location	Contribution
Alan Chalil, MD, MSc	Department of Clinical Neurological Sciences, University Hospital, London, ON, Canada	Writing and editing the initial manuscript and revising the manuscript (first and second rounds of revision)
Carmen S. Baker, MD	Department of Physical Medicine and Rehabilitation, University Hospital, London, ON, Canada	Writing and editing the initial manuscript and background/introduction review

Appendix (continued)

Author	Location	Contribution
Robert B. Johnston, MD	Department of Clinical Neurological Sciences, University Hospital, London, ON, Canada	Background/introduction review
Caroline Just, MD, FRCPC	Department of Clinical Neurological Sciences, University Hospital, London, ON, Canada	Researching mechanism of hemorrhage and provided revisions and responses to reviewers in first round of revisions
Derek B. Debicki, MD, PhD, FRCPC	Department of Clinical Neurological Sciences, University Hospital, London, ON, Canada	Researching mechanism of hemorrhage and provided revisions and responses to reviewers in first round of revisions
Michael S. Mayich, MD, FRCPC	Department of Medical Imaging, University Hospital, London, ON, Canada	Figures and radiologic interpretation of CT and MRI in the Discussion section
Karen J. Bosma, MD, FRCPC	Department of Medicine, University Hospital, London, ON, Canada	Editing and reviewing the case presentation and course in the intensive care unit
David A. Steven, MD, MPH, FRCSC, FACS	Department of Clinical Neurological Sciences, University Hospital, London, ON, Canada	Most responsible physician; editing and reviewing the initial manuscript; editing and reviewing the final manuscript and responses to reviewers' comments; and corresponding author with the journal

References

- Shereen MA, Khan S, Kazmi A, Bashir N, Siddique R. COVID-19 infection: origin, transmission, and characteristics of human coronaviruses. *J Adv Res* 2020;24:91–98.
- Stock JH, Aspelund KM, Droste M, Walker CD. Identification and Estimation of Undetected COVID-19 Cases Using Testing Data from Iceland. *medRxiv* 2020:2020.2004.2006.20055582.
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061–1069.
- Asia Filatov PS, Hindi F, Patricio S. Espinosa neurological complications of coronavirus disease (COVID-19). *Encephalopathy Cureus* 2020;12:e7352.
- Mao L, Jin H, Wang M, et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. *JAMA Neurol* 2020;77:683–690.
- Poyiadji N, Shahin G, Noujaim D, Stone M, Patel S, Griffith B. COVID-19-associated acute hemorrhagic necrotizing encephalopathy: CT and MRI features. *Radiology Epub* 2020 Mar 31.
- Gibbs WN, Kreidie MA, Kim RC, Hasso AN. Acute hemorrhagic leukoencephalitis: neuroimaging features and neuropathologic diagnosis. *J Comput Assist Tomogr* 2005;29:689–693.
- Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061–1069.
- Cisse FA, Antoine JC, Pillet S, Jousserand G, Reynaud-Salard M, Camdessanche JP. Acute hemorrhagic leukoencephalopathy associated with influenza A (H1N1) virus. *J Neurol* 2011;258:513–514.
- Rosa Junior M, Borges EI, Fonseca APA, Fiorot JL, Balarini L, Valim V. Posterior reversible encephalopathy syndrome during treatment with tocilizumab in juvenile idiopathic arthritis. *Arq Neuropsiquiatr* 2018;76:720–721.
- Wu Y, Xu X, Chen Z, et al. Nervous system involvement after infection with COVID-19 and other coronaviruses. *Brain Behav Immun* 2020;87:18–22.
- Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. *Lancet* 2020;395:1033–1034.
- Lann MA, Lovell MA, Kleinschmidt-DeMasters BK. Acute hemorrhagic leukoencephalitis: a critical entity for forensic pathologists to recognize. *Am J Forensic Med Pathol* 2010;31:7–11.
- Jeganathan N, Fox M, Schneider J, Gurka D, Bleck T. Acute hemorrhagic leukoencephalopathy associated with influenza A (H1N1) virus. *Neurocrit Care* 2013;19:218–221.

Neurology® Clinical Practice

Acute Hemorrhagic Encephalitis Related to COVID-19

Alan Chalil, Carmen S. Baker, Robert B. Johnston, et al.

Neurol Clin Pract 2021;11:e147-e151 Published Online before print July 8, 2020

DOI 10.1212/CPJ.0000000000000900

This information is current as of July 8, 2020

Updated Information & Services	including high resolution figures, can be found at: http://cp.neurology.org/content/11/2/e147.full.html
References	This article cites 12 articles, 0 of which you can access for free at: http://cp.neurology.org/content/11/2/e147.full.html##ref-list-1
Subspecialty Collections	This article, along with others on similar topics, appears in the following collection(s): COVID-19 http://cp.neurology.org/cgi/collection/covid_19 Critical care http://cp.neurology.org/cgi/collection/critical_care CT http://cp.neurology.org/cgi/collection/ct Encephalitis http://cp.neurology.org/cgi/collection/encephalitis Intracerebral hemorrhage http://cp.neurology.org/cgi/collection/intracerebral_hemorrhage
Permissions & Licensing	Information about reproducing this article in parts (figures, tables) or in its entirety can be found online at: http://cp.neurology.org/misc/about.xhtml#permissions
Reprints	Information about ordering reprints can be found online: http://cp.neurology.org/misc/addir.xhtml#reprintsus

Neurol Clin Pract is an official journal of the American Academy of Neurology. Published continuously since 2011, it is now a bimonthly with 6 issues per year. Copyright © 2020 American Academy of Neurology. All rights reserved. Print ISSN: 2163-0402. Online ISSN: 2163-0933.